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                           INTRODUCTION
Hyperlipidemia one of the diagnostic criteria in nephrotic syndrome is usually 
observed during the active phase of illness and decreases with resolution of proteinuria. 
However persistent elevation of lipid fractions were observed in few studies52,94 and raise 
the question of later developing atherosclerosis and progression to chronic renal disease. 
Some studies point out  that there is a rationale in treating patients with persistently 
elevated lipid levels.10,95,67
 Our study aims to determine the proportion of various lipid fractions elevated in 
Nephrotic  syndrome  and  analyses  whether  there  is  persistent  Hyperlipidemia  after 
Remission.
Hyperlipidemia in childhood
The cholesterol levels measured in young men in their early 20s were predictive 
of the risk of developing coronary heart disease developing   3-4 decades later.
The  strongest  data  linking  factor  comes  from  Bogalosa  heart  study  and  the 
pathobiological determinants of atherosclerosis in youth research group.  These surveys 
have found significant correlations between early atherosclerotic changes, identified at 
autopsy of children and Both total and LDL cholesterol levels.
 …… Andrew M. Tershakovec and Daniel J. Rader  nelson 17 th edn
Children  at  risk  for  development  of  premature  atherosclerosis  in  adulthood 
(elevated cholesterol levels) should be identified early in life to reduce the associated 
risks  of  heart  disease.   Children  with  cholesterol  levels  greater  than  75th percentile, 
should be considered hypercholesterolemic and potentially at risk for adult heart disease.
A number  of  trials  have demonstrated that  cholesterol  reduction resulted  in  reduced 
angiographic progression of coronary disease and even modest regression in some cases.
           Plasma Lipid And Lipoprotein Levels  99
 During the first few months of life, cholesterol levels increase largely because of 
changes in LDL. Over the next 15-20 yr, in both males and females, there is little change 
in the total cholesterol level; the mean value fluctuates around 150-165 mg/dL. Mean 
LDL cholesterol levels remain slightly less than 100 mg/dL in both males and females 
during this period. 
                             HDL cholesterol levels are comparable in males and females early in 
life; they remain essentially constant in females but decline markedly in males during 
the 2nd decade to a level that is maintained through adulthood.       
                    Plasma triglyceride levels, in contrast, rise transiently in both males and 
females in the 1st year, fall to a mean of 50-60 mg/dL in the ensuing few years, and then 
rise to a mean of approximately 75 mg/dL by age 20 yr.
                        In early adulthood, there is a rise in plasma cholesterol that is almost exclusively caused 
by an increase in LDL cholesterol. The rate of increase over the next 30 yr is greater in males than in 
females. When coupled with their lower HDL cholesterol levels, this puts men at much greater risk 
than women for atherosclerotic heart disease, at least until women reach the age of menopause. 
Because of the changes in lipid levels with age, it is more appropriate to use age- and gender-specific 
percentile figures when comparing levels between individuals and over long periods rather than 
consider absolute cholesterol levels.  
PLASMA LIPOPROTEIN METABOLISM AND TRANSPORT99
Cholesterol and triglycerides are transported in the circulation in macromolecular 
complexes termed lipoproteins; the protein components of the complexes are called 
apolipoproteins. Dietary lipoproteins (chylomicrons) are formed in and secreted by the 
small intestine; VLDL is synthesized in the liver.HDL is secreted as nascent particles by 
the liver and small intestine and reach their mature form in the circulation only after 
exchange of components with other circulating lipoproteins or with tissues.
Transport of Exogenous (Dietary) Lipids.
Fatty acids (FA) and cholesterol (C) are esterified in the intestinal mucosa to form triglycerides (TG) 
and cholesteryl esters (CE), respectively. They combine with apoA and apoB-48 to form chylomicrons, 
which are secreted into the circulation. Chylomicrons undergo lipolysis in the capillary endothelium 
near adipose tissue and muscle tissue, losing TG via lipoprotein lipase (LPL), gaining apoE from HDL, 
and losing apoA and apoC to HDL. The resultant chylomicron remnants are taken up by hepatic apoE 
receptors for degradation by lysosomes. (Adapted from Havel RJ: Approach to the patient with 
hyperlipidemia. Med Clin North Am 1982;66:319.)
Pathways of VLDL and LDL metabolism in human plasma.
                
                      Triglycerides (TG) and cholesteryl esters (CE) are combined with 
apoB-100, apoC, and apoE in the liver and then secreted as VLDL, TG . VLDL undergo 
lipolysis in the capillary endothelium near adipose tissue and muscle tissue, losing TG 
via lipoprotein lipase (LPL). The resulting VLDL remnants are either converted to low-
density lipoproteins (LDL) for transport to peripheral cells via LDL receptor-mediated 
uptake or are taken up by hepatic receptors.. (Adapted from Havel RJ: Approach to the 
patient with hyperlipidemia. Med Clin North Am 1982;66:319
The role of VLDL in atherogenesis has been controversial . Some 
subpopulations of VLDL particles may have atherogenic  potential, while 
others do not . Small chylomicron remnant particles are implicated in the 
development and progression of CHD
High-Density Lipoprotein and Reverse Cholesterol Transport.  
In contrast to chylomicrons and VLDL, which are secreted into the circulation as mature 
particles, the liver and small intestine secrete HDL as nascent discoidal particles 
composed primarily of phospholipids and apolipoproteins. Nascent HDL secreted by the 
small intestine are rich in apoA-I and apoA-IV, whereas those derived from the liver 
contain predominantly apoA-I, and apoA-II.
                              Nascent lipid-poor apoA-I accepts unesterified cholesterol from 
tissues via a process that requires the ATP-binding cassette protein A1 (ABCA1), a 
cellular protein that facilitates the efflux of unesterified cholesterol and phospholipids 
from cells to apoA-1. Unesterified cholesterol in nascent HDL is esterified by the 
enzyme lecithin:cholesterol acyltransferase (LCAT), which is present on HDL, forming 
cholesteryl esters.
                                HDL cholesteryl esters may be selectively taken up by the liver via a 
hepatic HDL receptor called scavenger receptor class BI (SR-BI).         
                              Alternatively, HDL cholesteryl ester may transfer from HDL to 
VLDL and LDL by the cholesteryl ester transfer protein (CETP), after which it may be 
taken up by the liver or redistributed to peripheral tissues. Thus, HDL have two 
pathways by which they return tissue-derived cholesterol to the liver in a process that 
has been termed reverse cholesterol transport. HDL-derived cholesterol is either 
converted by the liver to bile acids or directly excreted into the bile.  
Secondary Hyperlipidemia
Most  of  the  Hypercholesterolemia  and  Hypertriglyceridemia  seen  in  clinical 
practice in children is secondary to other factors/disorders.
1. Obesity
2. Hypothyroidism
3. NEPHROTIC SYNDROME
4. Diabetis mellitus
5. Renal failure
6. Storage disease (glycogen storage, Taysach’s, Niemannpick)
7. Congenital biliary atresia and cholestasis 
8. Hepatitis, Anorexia nervosa, SLE
9. Alcohol intake, OCP pills
10.Drugs;- 13 cisretoinoic acid, thiazide diuretics, steroids, HIV protease inhibitors, 
Immuno suppressants and beta blockers
                            LITERATURE REVIEW
Nephrotic syndrome and Hyperlipidemia
Hyperlipidemia  is  one  of  the  cardinal  features  in  the  definition  of  nephrotic 
syndrome. It is generally believed that it almost always present in minimal change NS 
(MCNS) but it also can be found less frequently in other forms of nephrotic syndrome.
 Types of Hyperlipoproteinemia.
Attention has been only recently focused on the importance of defining the pattern 
of hyperlipoproteinemia, its severity and its complications.3,94 Plasma Lipoproteins are 
complexes of lipids and proteins that function to transport lipids, in a stable soluble 
form.
Neutral  fat,  Fatty  acids,  and  phospholipids  are  increased  as  markedly  as 
cholesterol.Fatty acids start to increase sooner than cholesterol levels.- Freidman  M 
Byers : Proc. Soc. Exp. Biol Med. 90 :496-499, 1955
Fat droplet deposition in renal tubules is believed to result form tubular absorption 
and  catabolism  of  lipoproteins.   Refractile  lipid  bodies  in  the  urinary  sediment  of 
nephrotic urine probably represent the excessive amount of lipoprotein excreted in the 
urine.  
- Heymann W, MakkerSp :  Prac. Pediatric : 178, 1974.
Serum total cholesterol and phospholipids levels are elevated more consistently 
than those of serum triglycerides.
  Increased levels of VLDL, IDL, and LDL are observed early in the course of 
Nephrotic  syndrome.   As  the  disease  worsens,  Triglyceride,  VLDL  levels  rise  at  a 
greater  rate than LDL  - Baxter JH, Goodman HC, Havel  RJ :  J  clinc Invest.  39 :  
455-465, 1960.
  HDL levels have been reported to be low, normal, or elevated in Nephrotic patients. 26,83,94
  HDL levels of those treated with non steroid drugs have normal limits of HDL 
cholesterol,  while those receiving the corticosteroids have higher values than control 
group …….. Nephron 1984: 37 (1): 49-53.77
It appears that elevated HDL is seen only in MCNS during relapse, but those with 
non-MCNS and persistent proteinuria tend to have a significant decrease in HDL.94
Serum total cholesterol and triglyceride levels were found to be greater than 95th 
percentile for age and sex in all patients with MCNS in relapse and those with Non 
MCNS and persistent proteinuria94.
 Degree of Hyperlipidemia.
The degree of Hyperlipidemia is also variable from one patient to another. Factors 
influencing the concentration of lipoproteins include the severity of the proteinuria, age, 
obesity,  use  of  corticosteroids,  diuretics,  β  blockers,  nutritional  state  and  degree  of 
residual renal function 95.
Mechanisms of Hyperlipidemia
            The  exact  mechanism(s)  responsible  for  the  hyperlipidemia  of  NS 
remains largely unknown.
- Most  evidence  suggests  increased  hepatic  synthesis  of 
lipoproteins as  the principal  cause.  It  appears  that  both decreased 
plasma  oncotic  pressure  and  lower  albumin  concentration,20,34 or 
decreased  plasma viscosity,92 are  stimuli  for  enhanced hepatocyte 
synthesis of lipoproteins and lipids.20,34
-  an  impaired  catabolism  due  to  decrease  in  lipoprotein lipase 
with slower removal of VLDL)90 
-  decrease  in  lecithin  cholesterol  acyltransferase,  with  reduced 
HDL  production.
- decreased LDL receptor activity and increased urinary 
       loss of HDL
       
 In the severe nephrotic state with plasma serum albumin under 2gm per dl,    HDL 
lipoproteinuria  produces a relative deficency of Lipoprotein lipase  activators ,which limits 
triglyceride clearance, aggravating the accumulation of VLDL. 
This would explain the rise of VLDL and triglyceride whenever the plasma serum 
albumin is under 2gm per dl15.
          In the mild form of NS, elevation of VLDL in the serum is due to 
overproduction  and is followed by a simultaneous increase in IDL(VLDL 
remnants) and LDL since the VLDL removal  mechanism is not saturated .26
           As the nephrotic syndrome worsens with serum albumins under 2gm per dl, the conversion 
of IDL to LDL is impaired and leads to progressive accumulation of IDL. Eventually in the more 
severe  forms , with serum albumin under 1gm per dl or in the presence of uremia, the catabolism 
of VLDL is also impaired because of the defect of lipoprotein lipase activity. As a consequence , 
triglyceride – rich VLDL and chylomicrons would accumulate in the serum whereas the 
concentration of IDL and LDL eventually may fall.26
                       In Nephrotic syndrome, VLDL and LDL are inversely related to 
HDL . It appears that the interconversation of VLDL to LDL is  affected . 
                        In addition , there are marked changes in the composition of all 
lipoprotein fractions. They contain more phospholipids and less protein than 
normal.
                        Elevation of  VLDL and LDL  is paralleled by a fall in HDL2 and 
in more severe cases ,fall in HDL3 . Since HDL is involved in the catabolism of 
VLDL , it is possible that the defect in HDL will contribute to the defective 
catabolism of VLDL and therefore, the accumulation of these lipoproteins.
 
Duration
Duration of Hyperlipidemia is also quite variable.  In many patients it is transient 
and correlates well with the activity of disease.  It is believed to be usually come down 
around 6-10 wks of disease activity,98  in others it may persist for prolonged periods.
Elevated cholesterol and LDH levels even after months or years in remission have 
been reported 94.
Studies on adults show that those Nephrotics who have persistent proteinuria have 
dyslipidemia  which  is  highly  atherogenic  and  probably  increases  the  incidence  of 
coronary heart disease. ……….. J med assoc. Thai  1993 sep 76(9). 
In a study on Indian adults, the average lipid values both in patients of nephrotic syndrome as 
well as control subjects were lower than those observed by western workers.  The HDL cholesterol 
values were significantly low in this study.44
In  a  few  studies  in  children,  prolonged  periods  of  Hyperlipidemia  even  after 
clinical  Remission  have  been   reported.   In  addition  some  of  these  children  have 
significantly altered HDL/LDL ratio.52,94 
     OTHER LIPID ABNORMALITIES
         1) Abnormal distribution of omega-6 fatty acids.  
Significantly  increased proportion of  arachidonic acid in plasma phospholipids 
and  elevated  proportions  of  linoleic  acid  in  triglycerides  of  subcutaneous  adipose 
tissue.59,93
2)Increased plasma levels of PG E2  and increased excretions of 6-keto PG F1α 
have been described in children with Idiopathic NS.24,33
3)The serum adiponectin levels during steroid – responsive nephrotic syndrome 
relapse was found to be high.
4) Apolipoprotein (a) size polymorphism is associated with Nephrotic syndrome. 
- Kidney Int 2004 Feb 65 (2)
5) IDL and Lp (a) remained above normal in Hypertiglyceridemic patients despite 
resolution of proteinuria  - Clin Chem.. 1995 Jun: 41.
The  Indian  patient  has  a  different,  dietary,  constitutional  and  genetic 
background.  Hence we undertook a study to determine the spectrum of 
lipid abnormalities in nephrotic syndrome in children.
Objective
Primary objectives:
1. To study the spectrum of Lipoprotein abnormalities in nephrotic syndrome before 
and after remission
2. To Identify patients with Hyperlipidemia even after remission.
Secondary objectives:
1. To compare the lipid levels after completing treatment with lipid levels of normal 
population
2. To find out whether lipid levels starts falling ,once urine protein becomes Nil or 
Trace.
3. To study the correlation between persistence and severity of lipid changes with 
duration of disease and frequency of relapses
                      MATERIALS & METHODS
Type of study
      Prospective, Observational study
Study population:
Children diagnosed to have Nephrotic syndrome in ICH & RC, GRH, Madurai
Study place :  Institute  of  child health and Research centre,  GRH, Madurai  medical 
college.
Duration: February 2004–Feb 2006 ( 2 years) .
Inclusion criteria
1. Children > 1 year with Nephrotic syndrome
2. Newly diagnosed as well as patients in relapse
Exclusion criteria
1. Age < 1 year
2. Family history of Hyperlipidemia  / Infantile stroke
3. Past h/o Hepatobiliary disorders, Hepatitis, RTA/CRF
4. Patients on β blockers, Retinoic acid, HIV protease inhibitors, thiazide diuretics, 
Immuno suppressants
5. Patients with storage disorders like glycogen storage,  Taysachs,  Niemann pick 
disorder 
STUDY DESIGN
      All newly diagnosed cases were admitted as Inpatients. Detailed History, thorough 
general and systemic examinations were done. The standard investigations like urine 
analysis for albumin, hyaline casts and RBC’s, 24 hour urinary protein, spot urine protein 
creatine ratio, serum protein, albumin, urea, creatine, mantoux, Xraychest, USG abdomen, 
urine c & s were done. All patients were adequately monitored with daily weight, BP, 
abdominal girth, I/O chart, and urine albumin.
    Patients previously diagnosed as nephrotic syndrome at our hospital, with relapse 
were also admitted. (i.e. during the disease activity)
 
 Three samples of blood were taken for each patient after overnight fast for serum lipid 
profile.
  I sample -> During disease activity
 II sample -> After Remission attained.
 III sample -> 2 weeks after completing steroid treatment in steroid responsive patients. 
In steroid dependent patients, sample was taken when remission was maintained with 
lowest possible dose of alternate day steroids   i.e during low dose steroid therapy.
 First sample was taken during admission. Further samples were taken during follow up 
at our Nephrology O.P., which is conducted every Monday morning 10.00- 12.00 A.M 
at the Department of Pediatrics, Govt Rajaji Hospital. Patients for whom samples to be 
taken are noted at o.p. are asked to come with over night fast and samples were taken the 
next day.
The blood samples taken were processed almost immediately, for further evaluation of 
total cholesterol(TC),triglycerides(TGL), and HDL using   specific enzymatic methods 
in Olympus auto analyzer.LDL was calculated using Fredrickson –Freidwald formula ;
(LDL= Total cholesterol – HDL-  TGL/5 ).and VLDL was calculated using the formula 
VLDL = TGL/5.
                                                                                    
DEFINITION OF VARIABLES 
The definitions & treatment regimen used in this study are based on the 
recommendations of Indian Pediatric Nephrology Group, Indian Academy of 
Pediatrics.
         NEPHROTIC SYNDROME
                1) PROTEINURIA
   a.Proteinuria is considered to be in the nephrotic range                
when the urine protein is 3+/4+ on a dipstick test, or                    
    B.Spotprotein/creatinine ratio>2mg/mg, or 
 c. urine    albumin >40 mg/m2 per hr (on a timed sample).
                2) HYPOALBUMINEMIA (SERUM ALBUMIN <2.5 G/DL)     
                              
     3) HYPERLIPIDEMIA      (SERUM CHOLESTEROL >200 MG/DL)                      
           
                4) EDEMA
  
       Table: 1 Definitions 
                                
Remission Urine albumin nil or trace (or proteinuria <4 mg/m2/h) for 3 consecutive days 
Relapse 
Urine albumin 3+ or 4+ (or proteinuria >40 mg/m2/h) for 3 consecutive days, 
having been in remission previously 
Frequent relapses 
Two or more relapses in six months of initial response, or more than three 
relapses in any twelve months 
Steroid dependence Two consecutive relapses when on alternate day steroids or within 14 days of 
its discontinuation 
Steroid resistance Absence of remission despite therapy with 4 weeks of daily prednisolone in a 
dose of 2 mg/kg per day
TREATMENT REGIMEN 
TREATMENT OF INITIAL EPISODE
                            The Expert Group recommends that the initial episode be treated with 
prednisolone administered in a dose of 2 mg/kg (maximum 60 mg) in two-three divided 
doses daily for six weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning 
dose on alternate days for the next six weeks. Treatment with prednisolone is then 
discontinued. Cortico-steroids should preferably be administered after meals.
TREATMENT OF RELAPSE 
The patient should be examined for infections, which are treated before initiating 
corticosteroid therapy. Prednisolone is administered in a dose of 2 mg/kg/day (single or 
two divided doses) until urine protein is trace or nil for 3 consecutive days, or for two 
weeks. Subsequently, prednisolone is given in a dose of 1.5 mg/kg on alternate days for 4 
weeks,and then discontinued. The usual duration of treatment for a relapse is thus 5-6 
weeks. Prolongation of therapy is not necessary for patients with infrequent relapses (see 
below). 
In case the patient is not in remission despite two weeks treatment with daily 
prednisolone, such treatment might be extended for two more weeks. Patients requiring 
daily corticosteroid therapy for more than 2 weeks, to induce remission, should be 
referred to a pediatric nephrologist for evaluation. 
                                                       Prednisolone 2mg/kg daily for 6 weeks
                                                       1.5 mg/kg alternate day for  6 weeks
               
              
   
First  Episode Of Nephrotic Syndrome 
Absence Of Hematuria, Hypertension, azotemia
Infrequent relapses
Frequent Relapses
Steroid Dependence
Steroid  Resistance
Refer For Evaluation
Define therapy based on 
renal biopsy findings
Refer For Evaluation
Alternate Day 
Prednisolone    To 
Maintain Remission
Assess Steroid Threshold
Prednisolone 2mg/kg  daily 
until remission , then 1.5 
mg/kg alternate days for 4 
weeks
Threshold < 0.5 mg/kg on 
alternate days
Threshold >0 .5 mg/kg on 
alternate days or steroid 
toxicity
Alternate day prednisolone for 
9-18 months
Levamisole 
Cyclophosphamide 
Cyclosporine A
                             RESULTS AND ANALYSIS
      Total no. of patients enrolled  = 70
      No of patients excluded from the study  = 5
      The Total number of patients included in the study  = 65 .
        Boys =40  and  girls = 25. 
       Steroid responsive = 53  (19 Girls + 34 boys) 
       Steroid dependent = 12   ( 6 girls + 6 boys).
        Table: 2
         AGE  DISTRIBUTION            
 
I. STEROID RESPONSIVE PATIENTS
         age Steroid 
responsive
Steroid.dependent
        1-4 yr 12 3
      5-9 30 5
  10-12 11 4
Table: 3
Mean Cholesterol Values Before, during and After Treatment in various age 
groups 
Total 
Cholest
erol
Before Treatment During treatment After treatment
Mean S.D. 'p' Mean S.D. 'p' Mean S.D. 'p'
Age 
Group
1-4 443 89
5-10 381 106
10-12 417 128
Total 402 109
0.2048 336 94
250 69
294 84
278 84
0.0317 144 17
142 18
140 29
142 20
0.7102
Sex
Male 395 92
Female 414 136
0.7951 279 75
275 100
0.3920 145 14
137 28
0.0122
Neither age nor sex has got, statistically significant impact on the total cholesterol level before 
treatment .But there is significant difference in the total cholesterol level in the various age groups 
during treatment,with 1-4 yr age group having high mean levels. There is significant difference in the 
total cholesterol levels between males and females after treatment i.e . males have higher mean total 
cholesterol values than females after treatment.
Table: 4
Mean TGL Values Before, During And After Treatment in steroid 
responders in various age groups
TGL Before Treatment During treatment After treatment
Mean S.D. 'p' Mean S.D. 'p' Mean S.
D.
'p'
Age 
Group
1-4 373 50
5-10 345 139
10-12 338 87
Total 349 115
0.7797 254 69
178 64
227 73
204 73
0.0049 98 31
101 23
88 23
98 25
0.1026
Sex
Male 351 104
Female 347 137
0.9704 198 66
214 86
0.5343 97 25
99 26
0.7877
Neither age nor sex has got, statistically  significant impact on the TGL level 
before treatment and after treatment. But there is significant difference in the TGL level 
in the various age groups during treatment.
Table: 5
Mean HDL Values Before, During and After 
Treatment In Steroid Responders in various age groups
                        
                                                 
HDL Before Treatment During treatment After treatment
Mean S.D. 'P' Mean S.D. 'P' Mean S.
D.
'P'
Age 
Group
1-4 41.6 3.4
5-10 42 5.6
10-12 41.4 2.8
Total 41.8 4.7
0.9498 43 4.1
42 2.4
45.5 16
42.9 7.6
0.8835 43.9 4.2
42.3 3.3
41.9 3.4
42.5 3.5
0.3598
Sex
Male 42.2 5.4
Female 41.2 3.0
0.6604 41.6 3.3
45.3 11.8
0.181 42.9 3.0
41.8 4.3
0.1164
There exists  no significant relationship between age & HDL levels and sex & 
HDL levels in before, during and after treatment.
Table:  6
Mean VLDL Values Before, During and After Treatment In Steroid 
Responders in various age groups
VLDL Before Treatment During treatment After treatment
Mean S.D. 'p' Mean S.D. 'p' Mean S.
D.
'p'
Age 
Group
1-4 74.5 10.1
5-10 69.1 27.5
10-12 67.4 17.2
Total 69.9 22.8
0.8168 49.5 10.1
35.4 12.9
47.1 17.9
40.8 14.8
0.0041 19.7 6.1
20.8 6.9
18 4.7
20 6.3
0.18
Sex
Male 70.2 20.4
Female 69.4 27.2
0.9630 40.5 14.7
41.2 15.3
0.8455 20.4 5
19.8 7.1
0.2724
Neither age nor sex has got, statistically  significant impact on the VLDL level 
before treatment  and after  treatment.But  there is  significant  difference in the VLDL 
level in the various age groups during treatment.
Table: 7 
Mean LDL values before, during and after treatment In Steroid Responders in 
various age groups
                      
LDL Before Treatment During treatment After treatment
Mean S.D. 'p' Mean S.D. 'p' Mean S.
D.
'p'
Age 
Group
1-4 327 93
5-10 262 97
10-12 295 152
Total 282 111
0.2105 228 98
167 66
234 63
194 79
0.015 80.8 19.
2
80.5 22.
7
81 27.
5
80.7 22.
6
0.9807
Sex
Male 275 96
Female 295 135
0.7455 200 78
183 81
0.2578 83 12.
7
76.5 34
0.0286
Neither age nor sex has got, statistically significant impact on the LDL levels before 
treatment .But there is significant difference in the LDL  level in the various age groups during 
treatment ,with 1-4 yr, 10-12 yr having high mean levels. There is significant difference in the LDL 
levels between males and females after treatment,with males having higher mean levels.
Table: 8 
Lipid Profile before and during treatment in 
steroid responders
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mea
n
S.D
.
Mea
n
S.D
.
Mea
n
S.D. Mean S.D.
Before 
Treatment
402 109 349 115 41.8 4.7 69.9 22.8 282 111
During 
Treatment
278 84 204 73 42.9 7.6 40.8 14.8 194 79
'p' value 0.0001 0.0001 0.0805 0.0001 0.0001
Statistically significant difference exists in the total cholesterol, TGL, VLDL and LDL levels 
before treatment and during treatment. HDL levels do not have significant difference
Table: 9  
Lipid Profile before and after treatment in steroid   responsive patients
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mea
n
S.D
.
Mea
n
S.D
.
Mea
n
S.D. Mean S.D.
Before 
Treatmen
t
402 109 349 115 41.8 4.7 69.9 22.8 282 111
After
Treatmen
t
142 20 98 25 42.5 3.5 20 6.3 80.7 22.6
'p' value 0.0001 0.0001 0.0805 0.0001 0.0001
Statistically significant difference exists in the total cholesterol, TGL, VLDL and LDL 
levels before treatment and after treatment. HDL levels do not have significant difference
Table: 10 
Lipid Profile During and after treatment in steroid responders
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mea
n
S.D
.
Mea
n
S.D
.
Mea
n
S.D. Mean S.D.
During 
Treatmen
t
278 84 204 73 42.9 7.6 40.8 14.8 194 79
After 
Treatmen
t
142 20 98 25 42.5 3.5 20 6.3 80.7 22.6
'p' value 0.0001 0.0001 0.7718 0.0001 0.0001
Statistically significant difference exists in the total cholesterol, TGL, VLDL and LDL levels 
before treatment and after treatment HDL levels do not have significant difference
Table: 11
Lipid Profile after treatment in steroid responders and Normal Indian 
children
                                             
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
After 
Treatment
142 20 98 25 42.5 3.5 20 6.3 80.7 22.6
Normal 
population 
(Indian 
value)
134.5 27.1 91.1 29.9 34.8 13.1 80.1 21.7
'p' value 0.1172 0.8618 0.0002 0.6846
There is no statistically significant difference in the total cholesterol, TGL and 
LDL levels of the patients after treatment from the Normal population levels (Indian 
Value). But the values of HDL are significantly higher than the normal Indian Value for 
the patients after treatment.
  
   
  II. Lipid Profile of Steroid Dependant Patients
Table: 12
Lipid Profile  During Relapse(Before Treatment) And  Remission 
(II)Sample In Steroid Dependent Patients
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mea
n
S.D
.
Mea
n
S.D
.
Mea
n
S.D. Mea
n
S.D.
Before 
Treatment
566 146 492 233 41.3 3.4 97.5 46.9 401 140
During 
Treatment(II) 
SAMPLE
284 113 198 152 42.2 5.2 39.8 31 195 99
'p' value 0.0003 0.0007 0.8607 0.001 0.0008
Statistically significant difference exists  in the total cholesterol, TGL, VLDL and 
LDL levels before treatment and during treatment. HDL levels do not have significant 
difference.
Table: 13
Lipid Profile During relapse and after prolonged remission (III sample) 
in steroid dependent patients
                                         
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mea
n
S.D
.
Mea
n
S.D
.
Mea
n
S.D. Mean S.D.
Before 
Treatmen
t
566 146 492 233 41.3 3.4 97.5 46.9 401 140
After 
prolonged 
remission 
(iii) 
sample
289 92 212 76 42.8 3.4 42.3 14.2 213 80
'p' value 0.0004 0.0007 0.2905 0.0007 0.0016
Statistically significant difference exists in the total cholesterol, TGL, VLDL and 
LDL levels before treatment and after prolonged remission IIIsample .HDL levels do not 
have significant difference
Table: 14
Lipid Profile During (II sample) and after prolonged remission (III 
sample) in steroid dependent patients
  Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mea
n
S.D
.
Mea
n
S.D
.
Mea
n
S.D. Mean S.D.
During 
Treatmen
t II 
sample
284 113 198 152 42.2 5.2 39.8 31 195 99
After 
prolonged 
remission 
III sample
289 92 212 76 42.8 3.4 42.3 14.2 213 80
'p' value 0.5636 0.1659 0.2333 0.1331 0.2853
There is no statistically significant difference in the total cholesterol, TGL,HDL,VLDL 
and  LDL  levels  of  the  patients  during  treatment  and  after  prolonged  remission  III 
sample.
Table: 15
Comparison of mean lipid values of Steroid responsive and 
Steroid dependant patients after treatment( III SAMPLES)
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
Steroid 
responsive
142 20 98 25 42.5 3.5 20 6.3 80.7 22.6
Steroid 
dependant
289 92 212 76 42.8 3.4 42.3 14.2 213 80
'p' value 0.0001 0.0001 0.9724 0.0001 0.0001
There is a statistically significant difference in the total cholesterol,  TGL,VLDL 
and LDL levels of the Steroid responsive and Steroid dependant patients after treatment. 
But there exists no significant difference in HDL values.
Table: 16 
Comparison of mean lipid values of Steroid dependant patients after 
treatment ( III sample)from Normal Indian population 
Total 
Cholestero
l
TGL HDL VLDL LDL
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D.
Steroid 
dependant
289 92 212 76 42.8 3.4 42.3 14.2 213 80
Normal 
Indian 
values 
134.5 27.1 91.1 29.9 34.8 13.1 80.1 21.7
'p' value 0.0001 0.0001 0.0287 0.0001
There is  statistically significant difference (ie increase)  in the total cholesterol, TGL,HDL and 
LDL levels of the Steroid dependant patients from the Normal population levels (Indian Value) after 
treatment.
                   
   Table: 17 
Percentage of Children exceeding recommended limits of intervention after 
treatment.
In steroid responsive 
patients only 1% were 
found to have elevated 
total cholesterol level & 
2% had elevated TGL & 
LDL  levels. In steroid 
dependent patients 100% 
patients have elevated 
total cholesterol & LDL 
levels. 83.3% patients 
have elevated TGL levels. 
 DISCUSSION
                     Total number of patients enrolled in the   present study was  seventy .Three 
patients were excluded from the study, as they had irregular follow up and treatment. 
Two patients were found to be steroid resistant and remission achieved in them  with 
I.V. cyclophosphamide , oral  prednisolone , A.C.E. inhibitors, and one of them  was 
treated with atorvostatin started by the nephrologist. Due to multiple factors ( drugs ) 
affecting lipid levels and a small subset,  these patients were also excluded from the 
study. 
     Hence totally five patients were excluded from the present study.
The Total number of patients included in our study was 65 out of which 40 were boys 
and 25 were girls. 53 patients were found to be steroid responsive (19 Girls + 34 boys) 
and twelve patients were found to be steroid dependent.  ( 6 girls + 6 boys).
Parameter STEROID 
RESPONSIVE 
children (N= 53)
STEROID 
DEPENDENT 
CHILDREN
(N= 12)
No % No %
Total Cholesterol 
> 200
1 1.9 12 100
TGL >150 2 3.8 10 83.3
HDL < 20 NIL - Nil
LDL > 130 2 3.8 12 100
TGL / HDL > 5.5 NIL - 3 25
LDL / HDL > 4.9 NIL - 5 41.6
Male to female ratio in the present study is 1:6:1.  The sex ratio in other studies range 
from 1.7 to 2.1.97,98. The Male to female ratio in steroid responsive cases is 1.78:1 & in 
steroid  dependent  cases  it  is  1:1  in  the  present  study.  Females  are  found  to  have 
relatively more complications than males in our study.
In our study, all the 5 lipid fractions, Total, TGL, HDL, VLDL, LDL were found 
to be elevated in both steroid responsive as well steroid dependent groups during disease 
activity. This is in contrast to other studies reporting only       Hypercholesterolemia, 
hypertriglyceridemia     – Nephron 1984 : 37 (1) 49-53.77  On the other hand, HDL levels 
have been reported to be low, normal or elevated in Nephrotic patients. 26,83,94.  European 
J. Clin  Invest. Gherardi E. et al.26, Vass VJ et al 83,  Zilleruelo, et al 94, J med thai, 1993.
Serum total  cholesterol,  TGL,  VLDL,  LDL,  Levels  were  found  to  be  >  95th 
percentile for age and sex in all patients of steroid responsive with relapse and in steroid 
dependent cases in the present study.  
          Zilleruelo, et al :  reported Total TGL levels > 95th percentile for age and 
sex in all patients with  MCNS and in those with persistent proteinuria,  but not for 
VLDL & LDL.94
AGE 
                      Most of the patients in our study belonged to 5-10 year age group.( school 
going age group).This may be due to the inclusion of relapse cases  also in the study. 
These patients had their first episode during the preschool age group.        
   
    Comparing  the  three  samples,  in  the  present  study  a  significant  difference  was 
observed between various age groups for levels of Total cholesterol, TGL, VLDL, and 
LDL  during  Treatment  (II  sample).  Mean  values  were  found  to  be  high  in  1-4  yr 
followed by 10 –12 yr age group than 5-10 yr age group. No significant difference was 
observed  among  age  groups  during  Relapse  /  Disease  activity  (I  sample)  and  after 
treatment (III samples). HDL levels have no significant difference among age groups.
SEX 
               A significant difference in mean levels of total cholesterol and  LDL was 
observed between males& females (males> females) in the third sample only  (ie. After 
treatment).  The higher LDL levels contributed to the higher total cholesterol observed . 
No sex difference observed among before (I) and during treatment( II sample) in steroid 
responsive patients.
  
Degree of Hyperlipidemia 
The mean cholesterol values before treatment (during relapse) in the present study 
was found to be  Total  402 + 109, TGL  349 + 115, HDL 41.8 + 4.7,   VLDL 69.9 + 
22.8, and LDL 282 + 111.   
   Zillerueloa et al,94   have reported in NS during relapse, a mean  total cholesterol 354 
mg/dl and mean TGL  249 mg/dl. comparing these values our mean values were found 
to be high.
Nipponshi reported a mean total cholesterol level of 401 + 174. in  adults, 
which is similar to our study.
In steroid dependent / frequent relapsers, the mean values of cholesterol in our 
study was Total 566  + 146, TGL  492  + 233,  HDL  41.3  + 3.4, VLDL 97.5  + 46.9, 
LDL 401 + 140 during relapse.
Zilleruelo et al 94 reported a mean total cholesterol 557 mg / dl and Trighyceride 
values 620 mg / dl respectively in Non –MCNS persistent proteinuria.
Duration 
In our study, hyperlipidemia is found to be transient in steroid responsive patients 
and the mean values were found to come to levels,  normal to Indian children.  The 
approximate duration is 8-14 weeks.  Because we took the third sample 2 weeks after 
completing treatment ,   sample was taken around 14 weeks for new cases and 8 weeks 
for relapses cases as per treatment protocol.
In steroid dependent / frequent relapsers, the mean values of all the fractions of 
cholesterol were found to be persistently high even when remission maintained with low 
dose  steroid  therapy.   Hence  even  in  prolonged  remission,  (ie.  No  proteinuria  ) 
Hyperlipidemia persists after 3-4 months of steroid therapy.
The  HDL level  in  both  the  groups  (steroid  responsive  & steroid  dependent  / 
Frequent Relapsers) does not differ significantly.  The mean HDL levels were found to 
be slightly elevated when compared to levels of Normal Indian children in our study. 
This is similar to another study reported by Sokolouskaya IV et al.  Nephron 1984 : 37 
(1) : 49-53.
Table: 18
Comparison with Normal population :
The Individual patient values after completing Treatment (III sample) of steroid responders 
were compared to the cut off levels recommended for intervention.
% of patients exceeding 
Recommended cut off 
levels for
Cut off levels used
Western 
children64
Indian2 
children
Western64 
children
Indian2 
children
Total 
cholesterol
1  (1.9%) 1 (1.9%) > 200 >190
TGL 19 2 (3.8%) > 95th 
percentile for 
age & sex
> 150
LDL 2 2 (3.8%) > 130 > 130
HDL - - - < 20
In our study, about 1.9% of children after treatment was found to have elevated 
total cholesterol  > 200 &  3.8% of children have elevated TGL  > 150 and LDL > 130 
when compared to Normal Indian children.
When compared to western Recommended levels64, more number of patients (i.e. 
19patients) have elevated TGL levels  > 95th percentile.  This is because the TGLs levels 
in reported studies of normal Indian Children itself  found to be higher than western 
population.2,64
The Two steroid responsive patients who have elevated Total, TGL, LDL levels at 
the third sample in our study were followed up and the samples were repeated 4 weeks 
after  III  sample.   These  new  levels  were  found  to  be  Normal  (ie.  Less  than  the 
recommended levels of interventions.
Hence,  in  our  study,  the hyperlipidemia in steroid responsive nephrotic 
children  comes to Normal (100%) in 12-14 weeks after completing treatment .
Steroid dependent patients :
All the steroid dependent / frequent relapses (100%)  in remission were found to 
have  elevated  lipid  levels  greater  than  the  recommended  limits  for  Intervention  as 
mentioned above.
      LIMITATIONS OF THE STUDY
1. Our study is  concerned with levels of various proportions of                                      
Lipoproteins in nephrotic syndrome. The various other                                   abnormal 
lipids like free fatty acids, phospholipids, and prostaglandins were not studied.
2.  The enzymatic studies like levels of lipoprotein lipase, LCAT – proposed 
mechanisms involved in hyperlipidemia were not studied due to limitation 
of resources.
3. The  exact  duration  of  hyperlipidemia  can’t  be  documented  as  it  needs 
multiple  weakly  samples  since  there  is  an  individual  variation  in  the 
duration of hyperlipidemia in nephrotic patients.
4. The  effect  of  steroid  as  a  separate  cause  of  hyperlipidemia  was  not 
evaluated in this study.
5. Hyperlipidemia in steroid resistant patients was not studied since remission 
is achieved in them with nonsteroid drugs, ace inhibitors and to study their 
effect on lipid profile , needs further studies . As Statins were started on 
these patients they were excluded from the study.
6. The  Various  Changes  in  the  composition  of  lipids  and  their  effect, 
documented in few other  studies could not  be done due to limitation of 
resources.
7. There is only one study available for normal lipid levels in Indian Children. 
In  our  study  HDL levels  found  to  be  elevated  when  comparing  Indian 
children. This needs further evaluation.
8. We have  not  done  normal  lipid  levels  in  children  in  our  region due  to 
limited resources.
                      
                    CONCLUSION 
The  following  conclusions  are  drawn  from  the  observations  of 
present study.
1. During disease activity  /  relapse,  all  the lipid fractions (Total,  TGL, HDL, 
LDL,  VLDL  were  elevated  in  all  of   both  steroid  responsive  and  steroid 
dependent patients.  
2. No significant  difference in  lipid levels  was observed between various age 
groups before and also after treatment.   Total cholesterol, LDL levels were 
found to have significant difference between males & females , after treatment, 
with males having higher mean values than females.
3. The mean total cholesterol, TGL, HDL, VLDL, LDL, values were found to be 
elevated  during  relapse  /  I  episode  and  started  decreasing  once  Remission 
attained.
4. In steroid responsive patients these mean values decrease further and reaches 
normal Indian children values except HDL which was found to be elevated. 
5. But the mean HDL levels were found to be elevated both during relapse and 
after treatment when compared to normal Indian children.2  Hence HDL levels 
were not found to be altered  in steroid responsive nephrotics.
6. In  steroid  dependent  patients,  lipid  values  elevated  during  relapse,  started 
decreasing once remission attained, but found to be persistently high even after 
prolonged remission with low dose steroid therapy.   All  the fractions were 
found to be elevated comparing normal Indian children.
7. The mean values of total  cholesterol,  TGL, VLDL, LDL were found to be 
higher in Frequent relapser  / steroid dependent patients than steroid responsive 
both during disease and Remission. But the HDL value does not significantly 
differ  between  these  two  groups.  These  high  values  needs  intervention  in 
steroid dependent / frequent relapsers.
Hence the degree of hyperlipidemia correlates with duration of 
disease and frequency of relapse.
8. 100% of steroid responsive patients have levels with in the recommended cut 
off limits for Indian children 12-14 weeks after completing steroid treatment.
9. Initial  elevated levels  observed in Third samples of  2 patients  which when 
repeated comes to normal indicates an individual variation in the duration of 
hyperlipidemia.
10. The  TGL levels  in  our  patients  were  found to  be  high  when  compared  to 
Western population, but was normal when compared with reported studies on 
Indian Children.
11. In steroid dependent / frequent relapsers, persistent hyperlipidemia observed 
even after prolonged remission.  These children should be further followed, 
monitored and diet, exercise therapy should be given as initial intervention.
                                         RECOMMENDATIONS
1. Based  on our  study,  a  routine  screening  of  lipid  profile  in  all  cases  of 
steroid responsive patients  cannot  be recommended considering the cost 
effective factor.
2. We recommend a routine lipid profile screening in all frequent relapsers 
and  steroid  dependent  nephrotic  syndrome  patients  after  prolonged 
remission.
3. At present, Diet Therapy, physical activity and weight management along 
with  Treatment  of  the  disease  can  be  recommended  in  these  persistent 
hyperlipidemic patients.
4. Since few percentage of patients (3.8%) found to be hyperlipidemic at III 
sample  in  steroid  responsive  patients,  we  recommend  studies  at  other 
tertiary centers for confirmation of duration of hyperlipidemia.
5. Further more, Since regular follow up is necessary in all nephrotic patients, 
a separate pediatric nephrology clinic should be conducted in every tertiary 
care  centre  particularly  in  teaching  hospitals  and  also  in  district  head 
quarters hospital.
6. A universal protocol should be used to diagnose, treat all these patients.
7. Further  studies  are  needed  to  study  the  efficacy  of  drugs  lowering 
cholesterol  levels  in  children  to  confirm safety  and  efficacy.  In  steroid 
dependent and steroid resistant cases.
8.  Further  studies  are  recommended  in  nephrotic  children  treated  with 
nonsteroid drugs to identify the drug effects on lipid levels.
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NAME OF THE PATIENT: UNIT   :
AGE/SEX         :           IP NO:
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OCCUPATION   :                                         FAMILY INCOME:
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o Y/N   H/O  SKIN INFECTION           
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• Y/N  LEUKEMIA /LYMPHOMA 
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EVALUATION RENAL BIOPSY
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